Synovial sarcoma (SS) is an aggressive soft-tissue sarcoma that is often discovered during adolescence and young adulthood. Despite the name, synovial sarcoma does not typically arise from a synoviocyte but instead arises in close proximity to bones. Previous work demonstrated that mice expressing the characteristic SS18-SSX fusion oncogene in myogenic factor 5–expressing (Myf5-expressing) cells develop fully penetrant sarcomagenesis, suggesting skeletal muscle progenitor cell origin. However, Myf5 is not restricted to committed myoblasts in embryos but is also expressed in multipotent mesenchymal progenitors. Here, we demonstrated that human SS and mouse tumors arising from SS18-SSX expression in the embryonic, but not postnatal, Myf5 lineage share an anatomic location that is frequently adjacent to bone. Additionally, we showed that SS can originate from periosteal cells expressing SS18-SSX alone and from preosteoblasts expressing the fusion oncogene accompanied by the added stabilization of β-catenin, which is a common secondary change in SS. Expression and secretion of the osteoclastogenesis inhibitory factor osteoprotegerin enabled early growth of SS18-SSX2–transformed cells, indicating a paracrine link between the bone and synovial sarcomagenesis. These findings explain the skeletal contact frequently observed in human SS and may provide alternate means of enabling SS18-SSX–driven oncogenesis in cells as differentiated as preosteoblasts.
Synovial sarcoma (SS) is an aggressive soft-tissue sarcoma that is often discovered during adolescence and young adulthood. Despite the name, synovial sarcoma does not typically arise from a synoviocyte but instead arises in close proximity to bones. Previous work demonstrated that mice expressing the characteristic SS18-SSX fusion oncogene in myogenic factor 5-expressing (Myf5-expressing) cells develop fully penetrant sarcomagenesis, suggesting skeletal muscle progenitor cell origin. However, Myf5 is not restricted to committed myoblasts in embryos but is also expressed in multipotent mesenchymal progenitors. Here, we demonstrated that human SS and mouse tumors arising from SS18-SSX expression in the embryonic, but not postnatal, Myf5 lineage share an anatomic location that is frequently adjacent to bone. Additionally, we showed that SS can originate from peristeal cells expressing SS18-SSX alone and from preosteoblasts expressing the fusion oncogene accompanied by the added stabilization of β-catenin, which is a common secondary change in SS. Exposure and secretion of the osteoclastogenesis inhibitory factor osteoprotegerin enabled early growth of SS18-SSX2-transformed cells, indicating a paracrine link between the bone and synovial sarcomagenesis. These findings explain the skeletal contact frequently observed in human SS and may provide alternate means of enabling SS18-SSX-driven oncogenesis in cells as differentiated as preosteoblasts.
stabilized tumors expressed higher levels of mesenchyme- and osteogenesis-related genes. This does not explicitly implicate, but may suggest, that these tumors derived from more bone-oriented cells of origin. Second, they also expressed more Opg (also known as Tnfrsf11b, which codes for osteoprotegerin, a secreted factor), which raised the possibility of microenvironmental effects of the bone. β-Catenin has been shown to drive the expression of OPG in osteoblasts (23, 24), the expression and secretion of which will shut down osteoclastogenesis as a RANKL dummy receptor (25, 26). Notably, OPG can also function as a dummy receptor for TRAIL, preventing extrinsic apoptosis (27). OPG expression is variable and generally low across reported human SS transcriptomes (28), and the elevated Opg expression observed in the group of β-catenin-stabilized mouse tumors could not be unambiguously attributed to tumor cells, as stromal cells or reactive bone tissue cells within the tumor tissue might alternatively account for its expression. However, as a secreted protein, OPG could function in a paracrine fashion to provide a sarcomagenesis-enabling environment. We sought to study the relationship between synovial sarcomagenesis and the skeleton by testing each of these hypotheses more thoroughly through genetic experiments in the mouse models.

Results

Synovial sarcomas appear in close proximity to bone. To determine whether a location adjacent to bone was relatively more common in SSs compared with other soft-tissue sarcomas, we analyzed a consecutive series of 48 human SSs. We observed that 40 of these SSs appeared to be directly juxtaposed to bone, without intervening periosteam (Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/JCI94955DS1, and Figure 1, A and B). Of the 8 SSs that were not juxtaposed to bone, 4 arose adjacent to the knee joint capsule and the rib cage (Figure 1, C–E, and Supplemental Figure 1A). A second control cohort of 28 consecutive soft-tissue sarcomas of nonsynovial histologic type included only 8 that even approached proximity to the skeleton (Supplemental Table 1 and Figure 1B). A second control cohort of 28 consecutive soft-tissue sarcomas of only pleiomorphic histology included 3 with growth in close proximity to the skeleton (Supplemental Table 1).

This anatomic location and proximity to bone was also recapitulated in our genetically engineered mouse models of SS. When we conditionally activated the Rosa26-LSL-SS18-SSX2-IRESeGFP (hSS2) allele in the Myf5Cre lineage, we frequently detected SSs next to bone, with the most common locations being in the extremities and the rib cage (Figure 1, C–E, and Supplemental Figure 1A). We previously observed that TATCre injections into peritibial tissues consistently produced tumors in hSS2 Ctnnb1fl/fl/WT mice, which express a floxed Ctnnb1 exon 3 (18). To test the tumor-originating capacity of other mesenchymal tissue compartments, we injected 8 hSS2 Ctnnb1fl/fl/WT littermate mice with 10 µl TATCre to delete Ctnnb1 exon 3 in cells within the tibialis anterior muscle adjacent to bone, in the contralateral quadriceps muscle distant from bone, and in the subcutaneous tissue of the abdominal wall. By 8 weeks after injection, each of the peritibial locations produced a tumor (Supplemental Figure 1B); none of the subcutaneous-only injections produced tumors (Supplemental Figure 1C).
Osteoprotegerin can enable synovial sarcomagenesis, but is not necessary for it. To test the potential contribution of paracrine OPG to synovial sarcomagenesis, we locally administered recombinant mouse OPG (rmOPG) every other day (or vehicle control) to 4-week-old wild-type (WT), heterozygous, or homozygous for a spontaneous loss-of-function mutant allele of Opg mice that were already developing tumors (Supplemental Figure 2). These data cannot prove that cells with osteogenic differentiation potential are the cells of origin for these tumors, but they suggest that synovial sarcomagenesis has an unusual predisposition for growing near the skeleton.

To test the impact of genetically removing Opg gene function, we bred mice to be WT, heterozygous, or homozygous for a spontaneous loss-of-function mutant allele of Opg as well as heterozygous for both Myf5Cre and hSS2. These were difficult experiments to perform, given that Myf5Cre hSS2 mice are already developmentally challenged, with severe kyphosis and weight loss that accompanies, but are independent of, tumorigenesis and likely results from Myf5 lineage loss (5, 7, 8). The added developmental side effects of lost OPG function led to the early death of the combination mutant mice as a result of morbidity that was also not tumor related (Supplemental Figure 2).

We repeated the experiment in mice via localized induction of SS by TATCre injection into homozygous hSS2 mice that were either homozygously WT or homozygously mutant for Opg. These mice lack the developmental side effects of Myf5Cre lineage transformation. These locally induced tumors developed more slowly in the mice lacking OPG (Figure 2D).

Embryonic Myf5Cre-expressing cells, but not postnatal myoblasts, can give rise to SS. To test whether postnatal myoblasts expressing Myf5Cre could give rise to SSs, an allele with SS18-SSX2 under the control of the TetO promoter, and separated from it by a floxed stop cassette, was targeted to a noncoding region in the RNA PolIII locus (this allele was termed hSS2T) (Figure 3A). Fourteen days postcoitum, embryonic fibroblasts, which were heterozygous for both the hSS2T allele and an allele that places the reverse tet transactivator (rtTA) in the Rosa26 locus behind a floxed stop (30), were harvested and recombined in vitro by the application of TATCre or vehicle and exposed to either doxycycline or saline control. These cells demonstrated a mild GFP signal from recombination of the rtTA allele, but stronger GFP fluorescence from the activation of the hSS2T allele after TATCre application and in the presence of doxycycline (Figure 2B).

Next, we bred mice to be triple-heterozygous for Myf5Cre, the conditional rtTA allele, and the hSS2T allele. Cohorts of these mice were provided drinking water with 0, 1, 2, or 6 mg/ml doxycycline and 5% sucrose continuously after weaning (3 weeks of age). We maintained these mice for over a year and found that no tumors had developed (Figure 3C; n > 25 per dose group). For a second cohort of mice, the parents were bred with continuous doxycycline exposure at the same doses (but therefore beginning from conception for the experimental mice). No pups were born to the breeding pairs exposed to the 6-mg/ml dose of doxycycline. Only 1 litter of 5 pups was born to 1 of the pairs exposed to 2 mg/ml doxycycline. Each of these mice formed tumors over the course of 1 year of continuous...
tracing after embryonic expression of Myf5Cre suggested that the lineage includes some degree of osteochondroprogenitor differentiation capacity (8). To evaluate osteochondroprogenitors for their SS-originating potential, we conditionally activated the hSS2 allele at various stages of osteoblast differentiation (Figure 4A). SS18-SSX2 expression in OcCre+ cells (mature osteoblasts) resulted in no offspring surviving beyond the first day of life (Figure 4A). Likewise, few pups survived to genotyping at age 2 weeks and even fewer beyond weaning at age 3 weeks among the Col1a1Cre+ hSS2+ double-heterozygotes (preosteoblasts, Figure 4A) (31). The 3 pups that survived had densely ossified skeletons, but no detectable tumors in the soft tissue or the bones (Figure 4, A–C). These results highlight the developmental toxicity of the fusion oncoprotein in osteoblasts and preosteoblasts during embryonic development, as dense expression of SS18-SSX2 across these entire lineages drives developmental failure without tumorigenesis. This also fit with previous data demonstrating that Prx1Cre was lethal as an embryonic initiator of the hSS2 allele (7).

To avoid embryonic/developmental toxicity of SS18-SSX expression across entire lineages, we turned our attention to tamoxifen-inducible Cre recombinase systems. Postnatal restriction of doxycycline exposure (Figure 3C). Of the 25 mice born under conditions of 1 mg/ml embryonic exposure, 2 formed tumors during the year of monitoring (Figure 3, C–F). These data suggest that the postnatal Myf5Cre lineage does not retain the SS-originating potential that it demonstrates embryonically and that myoblasts specifically may not harbor strong SS-originating potential.

To test the SS-originating potential of muscle progenitors 1 step earlier along the postnatal myogenic differentiation pathway, we induced SS18-SSX2 expression in the Pax7 lineage by tamoxifen dosing on day 5 or 8 of life in 2 cohorts of Pax7CreERT2+ hSS2+ mice. None of these mice developed tumors over the course of 1 year of monitoring (Figure 3C). Of note, while the myogenic precursors defined by the postnatal Myf5Cre or Pax7CreERT2 lineages showed no significant origination potential for SS from expression of SS18-SSX2, prior data from localized, lineage-nonspecific induction of hSS1 or hSS2 expression had already demonstrated that some postnatal cells in both periosteal and muscle compartments retained origination potential (5, 18).

SS18-SSX2 expression is tolerated by differentiating osteoblast precursors and transforms the more primitive of these. The nonmyogenic fraction of differentiated cell types marked from lineage tracing after embryonic expression of Myf5Cre suggested that the lineage includes some degree of osteochondroprogenitor differentiation capacity (8). To evaluate osteochondroprogenitors for their SS-originating potential, we conditionally activated the hSS2 allele at various stages of osteoblast differentiation (Figure 4A). SS18-SSX2 expression in OcCre+ cells (mature osteoblasts) resulted in no offspring surviving beyond the first day of life (Figure 4A). Likewise, few pups survived to genotyping at age 2 weeks and even fewer beyond weaning at age 3 weeks among the Col1a1Cre+ hSS2+ double-heterozygotes (preosteoblasts, Figure 4A) (31). The 3 pups that survived had densely ossified skeletons, but no detectable tumors in the soft tissue or the bones (Figure 4, A–C). These results highlight the developmental toxicity of the fusion oncoprotein in osteoblasts and preosteoblasts during embryonic development, as dense expression of SS18-SSX2 across these entire lineages drives developmental failure without tumorigenesis. This also fit with previous data demonstrating that Prx1Cre was lethal as an embryonic initiator of the hSS2 allele (7).

To avoid embryonic/developmental toxicity of SS18-SSX expression across entire lineages, we turned our attention to tamoxifen-inducible Cre recombinase systems. Postnatal restriction of
The Journal of Clinical Investigation

RESEARCH ARTICLE

211

jci.org   Volume 128   Number 1   January 2018

disorganized matrix and also evidence of continued expression of the fusion by EGFP (Figure 5, E–G). These data suggested that, among preosteoblasts, a subpopulation of cells tolerated SS18-SSX2 expression without malignant transformation. Extensive prior work had not identified any such cells that expressed the fusion but did not transform. Even cells in the Myf5Cre lineage were either destroyed or gave rise to tumors, in that we found no residual Cre-recombined, hSS2-expressing cells outside of the tumors in these mice.

The tumors that formed in the lower lips of Prx1CreERT2 hSS2 mice showed strong GFP fluorescence, indicative of fusion gene expression (Figure 6, A–C). Histologic sections showed spindle-shaped cells typical of SS, with characteristic immunohistochemical profiles (Figure 6, D–F). Cross-sectional analysis of the jaw revealed the close proximity of each tumor to the bone (Figure 6G). To verify the localized lineage restriction of Cre expression in the jaw/lip area, we analyzed Prx1CreERT2 Rosa26cre2+ mice at 3 weeks of age, following tamoxifen administration at 2 weeks of age. The expected periosteal mesenchymal progenitor cells of the mandible osterix (Osx) to preosteoblasts offered the opportunity to determine whether hSS2 could transform preosteoblasts without embryonic consequences (32, 33). After administering tamoxifen to 4-week-old OsxCreERT2 hSS2 mice, the mice were followed for 12 months and showed no sarcoma formation or any apparent skeletal phenotype (Figure 4, A and D). To induce SS18-SSX2 expression in earlier osteochondroprogenitors, we administered tamoxifen to 2-week-old Prx1CreERT2 hSS2 mice. Sarcomas developed in 6 of 7 mice, all on the lower lip, adjacent to the mandible (Figure 4, A and E).

Late OcCre hSS2 embryos, harvested prior to their perinatal demise, had dense bone formation and the apparent absence of hematopoietic progenitors in the marrow space (Figure 5, A and B). This niche-ablating effect has been described for the OcCre lineage in other conditional gene manipulations (24). Importantly, the spindled, marrow-replacing cells showed evidence of the recombined Rosa26 locus and expression of the fusion by the detected presence of its surrogate marker, EGFP (Figure 5, C and D). The few surviving Cola1Cre hSS2 mice also had shortened, but very dense, bones compared with those of the controls, with
were the sole lineage marked in these tracing experiments (Figure 6G). Notably, the adjacent enamel epithelium of the tooth has been shown to express and secrete high levels of OPG (34).

Stabilized β-catenin and SS18-SSX expression enhance sarcomagenesis in mesenchymal progenitors. Given the observed enhancement of tumorigenesis when stabilization of β-catenin accompanied localized activation of hSS2 (18), we combined the Ctnnb1ex3fl and hSS2 alleles under the control of Prx1Cre ERT2. Injection of tamoxifen into 2-week-old mice led to dramatic tumorigenesis, with the entire periosteal surface of the forelimb skeleton (the primary lineage of postnatal Prx1-expressing cells) erupting into massive tumors, all before the age of 3 months (Figure 7, A–I). Littermate control mice, lacking either hSS2 expression or β-catenin stabilization, produced no tumors within a similar time frame (Figure 7A). The Prx1CreER T2 hSS2 Ctnnb1tm11fl tumors had classic SS histologic features and immunohistochemical profiles (Figure 7, J–L).

Prx1CreER T2 Ctnnb1tm11fl littermates that lacked the hSS2 allele showed the impact of β-catenin stabilization on the Prx1CreER T2 lineage. These mice had a consistent phenotype at 1 year of age. Radiographs showed that the bones of the clavicle and forelimb had increased mineral density and thickened trabecular structure, respectively (Figure 8, A and B). Histopathology revealed an extensively thickened layer of periosteal undifferentiated mesenchyme in the forearm (Figure 8, C and D) and areas of both cartilaginous and osseous differentiation, as shown by Masson’s trichrome staining (Figure 8E). Each mouse of this genotype had also developed a bland, fibrous, tumor-like thickening of the mandible (Figure 8, F and G). The fibrous jaw masses had a microscopic appearance resembling the clinical entity termed an ossifying fibroma, with encapsulated islands of osteoid and cartilaginous matrix formation, each identified by Masson’s trichrome staining (Figure 8, H and I). The matrix islands contained no embedded osteocytes. Osteoblasts blocked from terminal differentiation would be excluded from the matrix they produce, as osteocyte embedding is linked to cell-cycle exit and terminal differentiation (35). The production of both osteoid and chondroid matrix con-
firmed the extended maintenance of an incompletely differentiated state, as along the course of mesenchymal differentiation, cells retaining both osteoblastic and chondrogenic characteristics precede those committed to either lineage (36).

β-Catenin stabilization enables SS18-SSX2–mediated transformation of preosteoblasts. Given the dramatic enhancement of sarcomagenesis from the addition of β-catenin stabilization to hSS2 activation in mesenchymal progenitors and the observation that this effectively blocked or slightly reversed the differentiation state of the lineage, we next tested whether such a shift along the differentiation pathway of osteoblasts could be effected in the OsxCreERT lineage by β-catenin stabilization. Mice were bred to bear heterozygosity for Ctnnb1ex3fl, hSS2, and OsxCreERT and injected with tamoxifen at 2 or 4 weeks of age. Triple-heterozygous mice also formed tumors that arose from much of the surface of the appendicular skeleton, with complete penetrance, and each tumor had classic SS histology and immunohistochemical profiles (Figure 9, A–I). Control mice, with activation of either hSS2 or Ctnnb1ex3fl alone in postnatal preosteoblasts, developed no tumors by 12 months of age (Figure 9A), but the latter allele revealed the developmental impact of β-catenin stabilization. Radiographic and histologic examination identified a fibro-osseous jaw mass in only 1 of 7 mice of this genotype (Supplemental Figure 3A). Triochrome staining revealed that the osteoid matrix islands within the fibroblastic proliferation in this mass contained no chondroid matrix (Supplemental Figure 3B). This lack of chondroid matrix correlated with the slightly later stage of osteoblast-directed differentiation at which β-catenin was stabilized in these mice, relative to the mice with β-catenin stabilization in the Prx1CreERT2 lineage (compare with Figure 8I).

OsxCreERT Ctnnb1ex3fl mice also showed an increased, osteopetrosis-like density in the mid-portions of the appendicular long bones, with or without the addition of hSS2 (Figure 9, B–E). The increased density in the long bones matched the trabecular morphology and position of the primary spongiosa that would have been present in these mice at the age of 4 weeks, when tamoxifen was administered (Figure 9, J and K), suggesting that the blockade to osteoclastogenesis was nearly complete in these portions of the bone. Bony trabeculae in these areas were thick and dense, as reflected in the area measurements from photomicrographs (Figure 9L), consistent with absent osteoclast activity. Tartrate-resistant acid phosphatase (TRAP) staining identified significantly fewer osteoclasts in these areas compared with that seen in the metaphyses of normal-bone, age-matched controls (Figure 9M).

Discussion

These data challenged our earlier interpretation that the SS-originating potential of the Myf5Cre lineage indicated a myoblast. We must now conclude that postnatal myoblasts and their postnatal myogenic precursors are unlikely candidates for the cell of origin implicated by the Myf5Cre lineage. Further, exogenous OPG had a paracrine impact, enabling early growth of SS18-SSX2–transforming cells, and genetic silencing of Opg slowed synovial sarcomagenesis. Finally, early mesenchymal progenitor cells with strong
osteoblast differentiation potential proved capable of tolerating SS18-SSX2 expression and even transformation from expression of SS18-SSX2, especially with the added boost of β-catenin stabilization. Thus, the observation that human SS often arises in close proximity to bones and often has areas of osteoid matrix production within the tumor can be explained by the transforming potential

in osteochondroprogenitors and by the additional enhancement of synovial sarcomagenesis from the paracrine secretion of OPG, which is highly expressed in bones. These observations also suggest an explanation of the typical age distribution for SS in adolescents and young adults. Both mesenchymal progenitor cell populations and OPG secretion diminish as humans age past young adulthood.
Mouse genetics experiments can provide proof of the sufficiency of specific combinations of cell lineages and transforming events for tumorigenesis but will never prove which cells truly give rise to similar tumor types in humans. Because the very character of each experiment results in tumorigenesis or no tumorigenesis, any untested variable may be the key between the two potential results. For example, elegant work by others has recently demonstrated that the sarcoma-generating potential of satellite cells in particular depends on their activation in response to injury (37, 38). Our experiments did not address the application of this principle to synovial sarcomagenesis, but future work should. Injury response or β-catenin stabilization may be the key missing ingredient in synovial sarcomagenesis from nontumor cells. Nonetheless, we cannot exclude the impact of cell-autonomous effects of lost OPG, because few human SSs express OPG directly, we assumed that we were testing the paracrine impact lost paracrine OPG from host tissues, such as bone, were combined in these experiments. Because few human SSs express OPG from nontumor cells. Nonetheless, we cannot exclude the impact of cell-autonomous effects of lost OPG, because the tumor cells also lacked functional Opg.

Mouse genetic experiments can also offer information regarding comparative efficiency, which, in the case of both the Ptx1 and Otx postnatal lineages, was the strongest seen in any model we have developed thus far. The addition of β-catenin stabilization to each of these originating lineages enabled both initiation (apparent by the additional numbers of tumors forming in each model) and progression (apparent by the rapid development of these tumors). Notwithstanding, these data cannot make a compelling argument that periosteal osteochondrogenitors are the cells of origin for human SS, as some human SSs arise in anatomic locations distant from the skeleton (such as primary pulmonary SSs); the efficiency data can only suggest that conditions may be suitable for such cells to potentially serve as a frequent cell of origin for SS case.

Finally, mouse genetic experiments can test the necessity of specific genes for transformation by their removal from otherwise efficient models of tumorigenesis. Such negative genetic experiments may be performed in the transforming cells or in the surrounding cells. By using a nonconditional germline mutant allele for Opg loss of function, we did not distinguish between these two. Therefore, both tumor cell-autonomous effects of lost OPG and lost paracrine OPG from host tissues, such as bone, were combined in these experiments. Because few human SSs express OPG directly, we assumed that we were testing the paracrine impact from nontumor cells. Nonetheless, we cannot exclude the impact of cell-autonomous effects of lost OPG, because the tumor cells also lacked functional Opg.

SS has been termed a stem cell malignancy (39). The stem-like state of SS cells may not derive entirely from a stem-like cell of origin, as even preosteoblasts gave rise to SSs with the appropriate inducement. Some level of differentiation must be reversible through the transformation process. If a periosteal cell requires no “second hit” more drastic than stabilization of β-catenin to render synovial sarcomagenesis efficient, it may achieve that stabilization in a variety of ways. APC-inactivating and β-catenin–stabilizing mutations have been described in approximately 20% of human SSs (19–22), but many other genetic, epigenetic, paracrine, and microenvironmental forces converge upon β-catenin stabilization. These alternate mechanisms of β-catenin stabilization are likely at work in a large portion of the poor-prognosis SSs with aberrant staining patterns for β-catenin. They may also provide alternate means of enabling SS18-SSX-driven oncogenesis in cells as differentiated as preosteoblasts.
For all comparison cohort experiments, littermate controls were used to mitigate any impact from the mixed SvJ and Bl/6 background. TATCre injections were 10 µl of a 42-µM concentration. rmOPG-Fc (R&D Systems) dissolved in saline vehicle was injected (2.5 mg/kg) into each anterior leg compartment every 48 hours. Doxycycline was mixed at the noted concentrations into 5% sucrose drinking water that was protected from light and changed every 72 hours. Caliper measurements of tumors were performed weekly in the proximal-to-distal and medial-to-lateral dimensions of the palpable hind limb tumors, and then the volumes were calculated by multiplying the longer dimension by the square of the shorter dimension, divided by 2.

Clinical. Consecutive SS patients were identified from a diagnostic search through pathology archives and included only if the molecular diagnosis was confirmed and if an MRI of the primary tumor prior to surgery was available. Soft-tissue sarcoma samples and MRIs were consecutively collected from control patients and confirmed not to have synovial histopathologic features.

Imaging. Radiographs of sedated mice were obtained using a Kodak Carestream 4000 Pro Fx imaging machine (Carestream Health Inc.).
Gross light and fluorescence images were obtained postmortem with a Leica AF6000 dissecting microscope (Leica Microsystems). Light microscopy was performed and images digitally photomicrographed using an Olympus BX43 microscope and a DP26 camera (Olympus America). CT images were acquired using an Inveon TriModality PET/ SPECT/CT Scanner (Siemens Preclinical Solutions). CT images consisting of 360 degrees and 540 projections were acquired first. The exposure time was 1.5 seconds, with detector settings at 80 kVp and 250 μA. Data were reconstructed onto a 1,056 × 1,056 × 1,728 image matrix using the COBRA software package (Exxim Computing Corp.). Consequently, the effective image voxel size was 47.1 μm (isotropic). Reconstructed images were analyzed and visualized using 3D Slicer, version 4.6.2 (45).

Trabecular area and GFP area measurements were performed using Photoshop (Adobe) to select and mark color-defined areas, and then ImageJ (NIH) to measure threshold areas.

**Histology.** Tissues were harvested postmortem, fixed in 4% paraformaldehyde overnight, decalcified (if including bone) in 14% ethylenediaminetetraacetic acid at pH 7.4 for 2 weeks at 4°C, and embedded in paraffin following serial dehydration in ethanol, or embedded and frozen in OCT (Sakura Finetek) following serial glucose gradient dehydration for X-gal staining. In addition to standard H&E staining, IHC was also performed for mouse TLE1 (1:50 dilution; clone M101; Santa Cruz Biotechnology); BCL2 (1:500 dilution; clone mhw-26; Santa Cruz Biotechnology); and EGFP (1:500 dilution; catalog OSE00003G; Thermo Fisher Scientific) using an IgG-HRP goat anti-rabbit secondary antibody (1:5,000 dilution; sc-2004; Santa Cruz Biotechnology); and EGFP (1:500 dilution; catalog OSE00003G; Thermo Fisher Scientific) using an IgG-HRP goat anti-rabbit secondary antibody (1:5,000 dilution; sc-2004; Santa Cruz Biotechnology) and counterstained with hematoxylin. TRAP cytochemical staining was performed by incubating slides at 37°C for 1 hour in phosphate-buffered 4% TRAP substrate solution (ARUP) and 0.016% pararosaniline and sodium nitrite, followed by hematoxylin counterstaining.

**Statistics.** The statistical analyses pertinent to each experiment are noted in the figure legends, including sample sizes. Statistical analyses were performed using a 2-tailed Student’s t test, with a P value of less than 0.05 considered significant.

**Study approval.** All mouse experiments were conducted with the approval of the IACUC of the University of Utah and in accordance with international legal and ethical standards. Clinical analyses were performed with approval from the IRB of the University of Utah and in accordance with legal and ethical standards. As only extant records were reviewed, the requirement for consent was waived by the IRB.

**Author contributions**

KBJ and MLH conceived the experiments. JJB, BEI, HJ, MLH, YW, MH and KBJ performed experiments. JJB, AG, and KBJ analyzed data. MRC contributed mice and resources. KBJ wrote the manuscript, and all authors edited it.

**Acknowledgments**

The authors express gratitude for the histology technical assistance of Sheryl Tripp at ARUP Laboratories (University of Utah) and the CT imaging performed at the Small Animal Imaging Core Facility (University of Utah). The Sarcoma Foundation of America, the Paul Nabil Bustany Memorial Fund for Synovial Sarcoma Research, and the Damon Runyon Cancer Research Foundation provided funding for this project. This work was also partly supported by grants R01CA201396 and P30CA42014 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

Address correspondence to: Kevin B. Jones, Huntsman Cancer Institute, 2000 Circle of Hope Drive, Room 4263, Salt Lake City, Utah 84112, USA. Phone: 801.585.0300; Email: kevin.jones@hci.utah.edu.

6. Gross light and fluorescence images were obtained postmortem with a Leica AF6000 dissecting microscope (Leica Microsystems). Light microscopy was performed and images digitally photomicrographed using an Olympus BX43 microscope and a DP26 camera (Olympus America). CT images were acquired using an Inveon TriModality PET/ SPECT/CT Scanner (Siemens Preclinical Solutions). CT images consisting of 360 degrees and 540 projections were acquired first. The exposure time was 1.5 seconds, with detector settings at 80 kVp and 250 μA. Data were reconstructed onto a 1,056 × 1,056 × 1,728 image matrix using the COBRA software package (Exxim Computing Corp.). Consequently, the effective image voxel size was 47.1 μm (isotropic). Reconstructed images were analyzed and visualized using 3D Slicer, version 4.6.2 (45).

Trabecular area and GFP area measurements were performed using Photoshop (Adobe) to select and mark color-defined areas, and then ImageJ (NIH) to measure threshold areas.

**Histology.** Tissues were harvested postmortem, fixed in 4% paraformaldehyde overnight, decalcified (if including bone) in 14% ethylenediaminetetraacetic acid at pH 7.4 for 2 weeks at 4°C, and embedded in paraffin following serial dehydration in ethanol, or embedded and frozen in OCT (Sakura Finetek) following serial glucose gradient dehydration for X-gal staining. In addition to standard H&E staining, IHC was also performed for mouse TLE1 (1:50 dilution; clone M101; Santa Cruz Biotechnology); BCL2 (1:500 dilution; clone mhw-26; Santa Cruz Biotechnology); and EGFP (1:500 dilution; catalog OSE00003G; Thermo Fisher Scientific) using an IgG-HRP goat anti-rabbit secondary antibody (1:5,000 dilution; sc-2004; Santa Cruz Biotechnology) and counterstained with hematoxylin. TRAP cytochemical staining was performed by incubating slides at 37°C for 1 hour in phosphate-buffered 4% TRAP substrate solution (ARUP) and 0.016% pararosaniline and sodium nitrite, followed by hematoxylin counterstaining.

**Statistics.** The statistical analyses pertinent to each experiment are noted in the figure legends, including sample sizes. Statistical analyses were performed using a 2-tailed Student’s t test, with a P value of less than 0.05 considered significant.

**Study approval.** All mouse experiments were conducted with the approval of the IACUC of the University of Utah and in accordance with international legal and ethical standards. Clinical analyses were performed with approval from the IRB of the University of Utah and in accordance with legal and ethical standards. As only extant records were reviewed, the requirement for consent was waived by the IRB.

**Author contributions**

KBJ and MLH conceived the experiments. JJB, BEI, HJ, MLH, YW, MH and KBJ performed experiments. JJB, AG, and KBJ analyzed data. MRC contributed mice and resources. KBJ wrote the manuscript, and all authors edited it.

**Acknowledgments**

The authors express gratitude for the histology technical assistance of Sheryl Tripp at ARUP Laboratories (University of Utah) and the CT imaging performed at the Small Animal Imaging Core Facility (University of Utah). The Sarcoma Foundation of America, the Paul Nabil Bustany Memorial Fund for Synovial Sarcoma Research, and the Damon Runyon Cancer Research Foundation provided funding for this project. This work was also partly supported by grants R01CA201396 and P30CA42014 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

Address correspondence to: Kevin B. Jones, Huntsman Cancer Institute, 2000 Circle of Hope Drive, Room 4263, Salt Lake City, Utah 84112, USA. Phone: 801.585.0300; Email: kevin.jones@hci.utah.edu.